Subscribe to our newsletter to receive the latest product updates and special offers

Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#1 / 200 Total
CRDF - Cardiff Oncology Inc - Stock Price Chart
TickerCRDF [NASD]
CompanyCardiff Oncology Inc
CountryUSA
IndustryBiotechnology
Market Cap152.80MEPS (ttm)-0.93
P/E-EPS this Y-4.22%
Forward P/E-EPS next Y-8.84%
PEG-EPS past 5Y35.42%
P/S311.84EPS next 5Y-
P/B2.19EPS Q/Q-7.34%
Dividend-Sales Q/Q21.87%
Insider Own8.07%Inst Own12.13%
Insider Trans0.84%Inst Trans-10.89%
Short Float2.89%EarningsFeb 29/a
Analyst Recom1.00Target Price7.00
Avg Volume929.79K52W Range0.94 - 3.07
Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. The firm's clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PACE GARY WDirectorDec 19Buy1.3730,00041,100697,761Dec 19 06:39 PM
MSTR - Microstrategy Inc. - Stock Price Chart
TickerMSTR [NASD, RUT]
CompanyMicrostrategy Inc.
CountryUSA
IndustrySoftware - Application
Market Cap21.70BEPS (ttm)28.18
P/E45.37EPS this Y-107.16%
Forward P/E-EPS next Y17.83%
PEG4.54EPS past 5Y68.04%
P/S43.73EPS next 5Y10.00%
P/B9.96EPS Q/Q122.64%
Dividend-Sales Q/Q-6.09%
Insider Own11.64%Inst Own49.43%
Insider Trans-13.47%Inst Trans-3.32%
Short Float20.05%EarningsFeb 06/a
Analyst Recom1.67Target Price794.17
Avg Volume1.48M52W Range188.30 - 1080.00
MicroStrategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SAYLOR MICHAEL JExecutive ChairmanFeb 29Option Exercise121.435,000607,1505,000Mar 01 04:26 PM
Montgomery JeanineSVP & CAOFeb 29Option Exercise404.601,000404,6001,491Mar 01 04:15 PM
Shao Wei-MingSEVP & General CounselFeb 29Option Exercise151.601,250189,5001,703Mar 01 04:14 PM
Patten Jarrod MDirectorFeb 29Option Exercise121.4342551,608425Mar 01 04:14 PM
SAYLOR MICHAEL JExecutive ChairmanFeb 29Sale1004.495,0005,022,4350Mar 01 04:26 PM
DTST - Data Storage Corp - Stock Price Chart
TickerDTST [NASD]
CompanyData Storage Corp
CountryUSA
IndustryInformation Technology Services
Market Cap39.51MEPS (ttm)-0.39
P/E-EPS this Y115.62%
Forward P/E27.43EPS next Y110.00%
PEG-EPS past 5Y-208.54%
P/S1.60EPS next 5Y-
P/B1.99EPS Q/Q168.61%
Dividend-Sales Q/Q35.47%
Insider Own44.07%Inst Own9.12%
Insider Trans0.00%Inst Trans6.77%
Short Float2.19%EarningsNov 14/b
Analyst Recom1.00Target Price9.00
Avg Volume52.47K52W Range1.60 - 4.75
Data Storage Corp. engages in the provision of business continuity services. These services include disaster recovery, infrastructure as a service, and cyber security. Its other services and solutions include data protection services, data center and security, voice and data solutions, and email archival solutions. The company was founded by Charles M. Piluso in June 2001 and is headquartered in Melville, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Argen JohnDirectorDec 26Option Exercise2.048331,69916,667Jan 03 08:57 PM
SWIN - Solowin Holdings - Stock Price Chart
TickerSWIN [NASD]
CompanySolowin Holdings
CountryHong Kong
IndustryCapital Markets
Market Cap212.38MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own82.76%Inst Own0.01%
Insider Trans0.00%Inst Trans-
Short Float6.26%Earnings-
Analyst Recom-Target Price-
Avg Volume154.77K52W Range1.84 - 13.25
Solowin Holdings engages in the provision of securities brokerage solutions through its subsidiary. It operates through the following segments: Securities Related Services, Investment Advisory Services, Asset Management Services, and Corporate. The Securities Related Services segment is involved in offering securities dealing and brokerage services, securities underwriting and placing services, and other financing services. The Investment Advisory Services segment offers investment solutions advisory services for clients, through a team consists of financial analysts, financial advisors, and investment managers. The Asset Management Services segment specializes in designing investment portfolios for investors with different risk appetite and to preserve the value of assets. The company was founded on July 23, 2021 and is headquartered in Hong Kong.
ENTX - Entera Bio Ltd - Stock Price Chart
TickerENTX [NASD]
CompanyEntera Bio Ltd
CountryIsrael
IndustryBiotechnology
Market Cap60.32MEPS (ttm)-0.34
P/E-EPS this Y28.89%
Forward P/E-EPS next Y-134.38%
PEG-EPS past 5Y13.96%
P/S6031.95EPS next 5Y-
P/B7.86EPS Q/Q22.44%
Dividend-Sales Q/Q-100.00%
Insider Own23.53%Inst Own11.45%
Insider Trans0.78%Inst Trans-4.00%
Short Float0.10%EarningsNov 14/b
Analyst Recom1.00Target Price10.00
Avg Volume104.07K52W Range0.52 - 1.48
Today 08:30AM Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +18.06%
Jan-30-24 08:30AM Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-03-24 08:00AM Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule (GlobeNewswire)
Dec-26-23 08:00AM Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025 (GlobeNewswire)
Nov-29-23 08:30AM Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform (GlobeNewswire)
Nov-14-23 07:30AM Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development (GlobeNewswire)
Nov-09-23 02:30PM Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis (GlobeNewswire) +20.64%
Oct-16-23 08:00AM Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting (GlobeNewswire)
Sep-13-23 01:18PM OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations (Zacks)
Sep-12-23 08:30AM Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes (GlobeNewswire)
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Taitel HayaDirectorJan 12Buy0.999,5009,40535,115Jan 16 08:00 AM
Taitel HayaDirectorJan 10Buy0.777,6155,86425,615Jan 11 06:14 PM
Toledano Miranda JayneChief Executive OfficerDec 22Buy0.7123,95217,006110,752Dec 27 08:27 AM
LIEBERMAN GERALD MDirectorDec 22Buy0.7123,95217,006226,961Dec 27 05:00 PM
Taitel HayaDirectorAug 22Buy0.6218,00011,21618,000Aug 24 08:12 AM
FLYX - flyExclusive Inc. - Stock Price Chart
TickerFLYX [AMEX]
CompanyflyExclusive Inc.
CountryUSA
IndustryAirlines
Market Cap267.06MEPS (ttm)0.12
P/E130.80EPS this Y146.15%
Forward P/E43.06EPS next Y200.00%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B5.63EPS Q/Q1670.83%
Dividend-Sales Q/Q-
Insider Own6.52%Inst Own7.99%
Insider Trans0.00%Inst Trans0.51%
Short Float0.97%Earnings-
Analyst Recom1.00Target Price9.00
Avg Volume33.86K52W Range3.71 - 15.00
flyExclusive, Inc. is a FAA regulated operator of private jet experiences offering customers on-demand charter, Jet Club and fractional jet services to destinations across the globe. It manages all aspects of the customer experience, in-house maintenance, repair and overhaul services, including paint, interiors and avionics capabilities, The company was founded by Thomas J. Segrave, Jr. in 2015 and is headquartered in Kinston, NC.
BBAI - BigBear.ai Holdings Inc - Stock Price Chart
TickerBBAI [NYSE, RUT]
CompanyBigBear.ai Holdings Inc
CountryUSA
IndustryInformation Technology Services
Market Cap720.22MEPS (ttm)-0.54
P/E-EPS this Y70.53%
Forward P/E-EPS next Y23.57%
PEG-EPS past 5Y-
P/S4.65EPS next 5Y-
P/B-EPS Q/Q119.83%
Dividend-Sales Q/Q-16.39%
Insider Own68.03%Inst Own7.57%
Insider Trans-0.26%Inst Trans-27.09%
Short Float19.45%EarningsMar 07/a
Analyst Recom2.00Target Price3.38
Avg Volume5.26M52W Range1.16 - 4.18
BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in Columbia, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Braden Pamela JoyceDirectorDec 15Buy1.9250,02596,048305,457Dec 21 05:21 PM
Dinu RalucaDirectorDec 15Sale1.9213,02925,016773,374Dec 18 06:57 AM
Katz Avi SDirectorDec 15Sale1.9213,02825,014773,375Dec 18 06:56 AM
Katz Avi SDirectorDec 13Sale1.8150,00090,500786,403Dec 15 06:55 AM
Dinu RalucaDirectorDec 13Sale1.8150,00090,500786,403Dec 15 06:52 AM
ABSI - Absci Corp - Stock Price Chart
TickerABSI [NASD]
CompanyAbsci Corp
CountryUSA
IndustryBiotechnology
Market Cap525.58MEPS (ttm)-1.16
P/E-EPS this Y8.35%
Forward P/E-EPS next Y35.67%
PEG-EPS past 5Y-
P/S75.73EPS next 5Y23.30%
P/B2.68EPS Q/Q20.29%
Dividend-Sales Q/Q-68.59%
Insider Own26.94%Inst Own36.36%
Insider Trans0.00%Inst Trans3.26%
Short Float13.82%EarningsNov 14/a
Analyst Recom1.40Target Price6.33
Avg Volume1.63M52W Range1.11 - 5.58
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.
NGNE - Neurogene Inc - Stock Price Chart
TickerNGNE [NASD]
CompanyNeurogene Inc
CountryUSA
IndustryBiotechnology
Market Cap505.24MEPS (ttm)-1.02
P/E-EPS this Y37.30%
Forward P/E-EPS next Y7.16%
PEG-EPS past 5Y13.40%
P/S-EPS next 5Y25.10%
P/B4.61EPS Q/Q-72.32%
Dividend-Sales Q/Q-
Insider Own9.89%Inst Own62.13%
Insider Trans0.00%Inst Trans-32.65%
Short Float1.34%Earnings-
Analyst Recom1.00Target Price44.50
Avg Volume71.87K52W Range9.80 - 34.73
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in January 2018 and is headquartered in New York, NY.
AQST - Aquestive Therapeutics Inc - Stock Price Chart
TickerAQST [NASD]
CompanyAquestive Therapeutics Inc
CountryUSA
IndustryDrug Manufacturers - Specialty & Generic
Market Cap279.10MEPS (ttm)-0.25
P/E-EPS this Y88.84%
Forward P/E-EPS next Y-138.67%
PEG-EPS past 5Y-19.73%
P/S5.81EPS next 5Y-
P/B-EPS Q/Q86.57%
Dividend-Sales Q/Q13.43%
Insider Own5.70%Inst Own35.64%
Insider Trans0.00%Inst Trans-3.98%
Short Float3.16%EarningsMar 05/a
Analyst Recom1.00Target Price6.33
Avg Volume997.01K52W Range0.72 - 4.39
Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients' therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.
1234561020